Douglas MacDonald

Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras

Peptide-binding specificity prediction using fine-tuned protein structure prediction networks

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy